Kaleido Biosciences, Inc. (KLDO)
| Market Cap | 454.09M |
| Revenue (ttm) | 732,000 |
| Net Income (ttm) | -81.12M |
| Shares Out | 35.55M |
| EPS (ttm) | -2.54 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 26 |
| Last Price | $12.62 |
| Previous Close | $12.44 |
| Change ($) | 0.18 |
| Change (%) | 1.45% |
| Day's Open | 12.49 |
| Day's Range | 12.26 - 13.03 |
| Day's Volume | 73,214 |
| 52-Week Range | 3.62 - 13.61 |
LEXINGTON, Mass., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), today announced Johan van Hylckama Vlieg, Ph.D., Chief Scientific Officer, will present at the Key...
Preliminary analysis (n=176) demonstrates favorable safety and tolerability; data provide a strong signal of clinical benefit for subjects reporting one or more comorbidities
LEXINGTON, Mass., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc., (Nasdaq: KLDO) today announced that Dan Menichella, Chief Executive Officer, will present at the 39th Annual J.P....
Topline data for two studies of KB109 are expected in the first quarter of 2021 Topline data for two studies of KB109 are expected in the first quarter of 2021
While most of Wall Street focuses on large- and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.
LEXINGTON, Mass., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), today announced that Dan Menichella, Chief Executive Officer, will participate in a fireside chat ...
- Topline Data for KB109 for the Treatment of Mild-to-Moderate COVID-19 Expected in the First Quarter of 202 1 -
Ex vivo data from candidate KB109, under evaluation in two clinical studies for COVID-19, to be presented at IDWeek 2020
LEXINGTON, Mass., Oct. 06, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), today announced an update to its ongoing COVID-19 clinical development program evaluating KB109 wh...
LEXINGTON, Mass., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to targeting the microbiome t...
Why Kaleido Stock Is Taking Off, And Why It Can Go Higher
Top-line safety, tolerability and activity results expected in mid-2021 Top-line safety, tolerability and activity results expected in mid-2021
LEXINGTON, Mass., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), today announced that Michael Bonney, Executive Chair, will participate in the following upcomin...
LEXINGTON, Mass., Aug. 27, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO) today announced that data from Microbiome Metabolic Therapy (MMT™) candidate KB174 for hepatic en...
- COVID-19 Clinical Development Program Topline Data Readout of Multi-Center Study Expected in Q4 2020 -
- Second Study Launched in Kaleido’s COVID-19 Clinical Development Program for this Rapidly Growing Patient Population -
While most of Wall Street focuses on large and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.
- Alison Lawton to step down as President and Chief Executive Officer to attend to a family health matter
LEXINGTON, Mass., June 08, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to targeting the microbiome...
LEXINGTON, Mass., June 01, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to targeting the microbiome...
LEXINGTON, Mass., June 01, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to targeting the microbiome...
Kaleido Biosciences, Inc. (KLDO) CEO Alison Lawton on Q1 2020 Results - Earnings Call Transcript
- Initiating Clinical Studies of KB109 in Outpatients with Mild-to-Moderate COVID-19; Data Anticipated in Q4 2020 -
- Top-Line Data from Study of Approximately 350 Patients Expected in Q4 2020 -
LEXINGTON, Mass., April 03, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to leveraging the microb...
Is (KLDO) Outperforming Other Medical Stocks This Year?
The Super Bowl of healthcare kicked off early for these companies.
LEXINGTON, Mass., Jan. 09, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc . (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to leveraging the microbi...
About KLDO
Kaleido Biosciences, a clinical-stage healthcare company, develops microbiome metabolic therapies. The company offers product candidates for the treatment of urea cycle disorders; hepatic encephalopathy; infections caused by multi-drug resistant bacteria; cardiometabolic and liver diseases; and immune oncology. It has a collaboration agreement with Gustave Roussy Cancer Center to develop microbiome metabolic therapies in immuno-oncology; a research collaboration with Washington University School of Medicine to explore the influence of microbiom... [Read more...]
| Industry Biotechnology | IPO Date Feb 28, 2019 |
| Stock Exchange NASDAQ | Ticker Symbol KLDO |
Analyst Forecasts
According to 6 analysts, the average rating for KLDO stock is "Buy." The 12-month stock price forecast is 15.42, which is an increase of 22.19% from the latest price.